Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment (Surgical and Non-surgical), By Distribution Channel (Hospitals, Cancer Institutes, Ambulatory Surgical Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis, and Forecast till 2029

Cutaneous squamous cell carcinoma treatment market accounted for US$ 10.9 billion in 2020 and is estimated to be US$ 21.0 billion by 2029 and is anticipated to register a CAGR of 7.5%. 

Cutaneous squamous cell carcinoma is the most common type of non-melanoma or keratinocyte skin cancer. It is an invasive disease that grows beyond the epidermis. Cutaneous squamous cell carcinoma is a type of cancer which results in malignant proliferation of cutaneous epithelium indicating 20% to 50% skin cancer. Cutaneous squamous cell carcinoma is associated with a substantial risk of metastasis. Cumulative exposure to sunlight, exposure to X-ray or certain other chemicals are the prime factors for developing cutaneous squamous cell carcinoma. According to the Skin Cancer Foundation report, 2019, more than 9,500 people are diagnosed with skin cancer every day in the US. Apart from this, according to the American Cancer Society 2019 statistics, an estimate of 5.4 million squamous and basal cell skin cancers are diagnosed each year in the US.

Impact of Covid-19 pandemic on market

With the outbreak of the COVID-19, various businesses are at the forefront to combat this pandemic. The pandemic has hindered the industrial supply chain and also disrupted the product segment. Government across the countries has imposed strict lockdown to limit the spread of disease. COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in Application, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another. Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds, which are used for manufacturing drugs such as cutaneous squamous cell carcinoma treatment and this is expected to hamper the market growth in the near future. This report will quantify the impact of a pandemic on the cutaneous squamous cell carcinoma treatment market.

The cutaneous squamous cell carcinoma market is expected to be driven by increase in the geriatric population, rise in intensity of ambient light which is considered a major factor for the cause of cutaneous squamous cell carcinoma, and introduction of new drugs and therapies for skin cancers. According to the American Cancer Society, around 2 in 10 skin cancer cases are squamous cell carcinomas (also called squamous cell cancers). Taking into account only the invasive forms of cancer, cutaneous squamous cell carcinoma is the second most common form of non-melanoma skin cancer (NMSC) and accounts for 20% of all cutaneous malignancies. This type of cancer starts from the flat cells of the epidermis. The cancer usually appears in the parts or areas of the body that are exposed to sun such as face, neck, ears, lips and hands.

Increase in prevalence of cutaneous squamous cell carcinoma

The cutaneous squamous cell carcinoma market is expected to register significant growth in the market owing to increase in prevalence of cutaneous squamous cell carcinoma, advancement in research and development in developing novel therapeutics, increasing launch of new drugs into the market, rising pipeline portfolio of various companies are some of the factor which will drive the cutaneous squamous cell carcinoma market. However, increase in complications rate, lack of early detection of the diseases may hamper the growth of the cutaneous squamous cell carcinoma market. Moreover, cost associated with branded drugs and lack of health insurance in developing countries may also hinder the growth of the cutaneous squamous cell carcinoma market.

The cutaneous squamous cell carcinoma treatment market is segmented based on treatment, distribution channel, and region.

On the basis of treatment, the cutaneous squamous cell carcinoma treatment market is segmented into surgical and non-surgical. Based on distribution channel, the market is segmented into hospitals, cancer institutes, ambulatory surgical centers, and others.

Regional Insights:

On region the cutaneous squamous cell carcinoma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for prominent share of the market during the forecast period. Increase in geriatric population, rise in patient population, and large number of research and development activities in cancer diagnosis and treatment are expected to fuel the growth of the market in the region. Moreover, favorable reimbursement policies, developed health care infrastructure, and rise in funding by governments for cancer treatment are anticipated to propel the market during the forecast period.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the cutaneous squamous cell carcinoma treatment market report based on treatment, distribution channel, and region.

Cutaneous Squamous Cell Carcinoma Treatment Market, By Treatment:

• Surgical
• Non-surgical

Cutaneous Squamous Cell Carcinoma Treatment Market, By Distribution Channel:

• Hospitals
• Cancer Institutes
• Ambulatory Surgical Centers
• Others

Cutaneous Squamous Cell Carcinoma Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • U.S.
  • Canada

The key players operating in the cutaneous squamous cell carcinoma treatment market includes Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In December 2016, Vidac Pharma, a clinical-stage oncology-focused pharmaceutical company, announced about the Phase II study of VDA-1102 ointment, a potent selective VDAC/HK2 modulator in actinic keratosis (AK). The drug candidate is being developed for first-in-class treatment for actinic keratosis, an early form of cutaneous squamous cell carcinoma (cSCC) featuring potency, safety, and tolerability at the same time.

• Eli Lilly and Company
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Sanofi S.A.
• Cadila Healthcare Limited
• Cipla Limited
• Castle Biosciences
• Regeneron Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Vidac Pharma
• LEO Pharma A/S
• Regeneron Pharmaceuticals, Inc.
• Merck Sharp & Dohme
• Amgen Inc